Health economic models in hemophilia A and utility assumptions from a clinician's perspective

Michele Valente, Paolo A. Cortesi, Giuseppe Lassandro, Prasad Mathew, Jennifer Pocoski, Angelo C. Molinari, Lorenzo G. Mantovani, Paola Giordano

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The clinical benefits of prophylaxis in patients with hemophilia are well-established and include the following: reduced bleeding episodes, prevention of joint damage, decreased inhibitor development, and improved health-related quality of life. However, the cost-effectiveness of prophylaxis is still not clear. Procedures: We reviewed the published hemophilia prophylaxis economic models focusing on utility assumptions. Results: We found six cost-utility studies that compared prophylaxis and on-demand regimens. These studies reported remarkably different results, using utility values based on different assumptions and data sources. Conclusions: We suggest that cooperation among key stakeholders (clinicians, patient organizations and health-care decision makers) as a means of collecting evidence-based and experiential data to represent both the utility and the quality of life changes for patients with Hemophilia A who are treated with prophylaxis or receive on-demand treatments may represent a winning strategy with which to resolve the outstanding issues related to health technology assessments in the care of patients with hemophilia. Pediatr Blood Cancer 2015;62:1826-1831.

Original languageEnglish
Pages (from-to)1826-1831
Number of pages6
JournalPediatric Blood and Cancer
Volume62
Issue number10
DOIs
Publication statusPublished - Oct 1 2015

Keywords

  • Cost Utility Analysis (CUA)
  • Health Technology Assessment (HTA)
  • Health-related quality of life (HRQoL)
  • Hemophilia
  • Prophylaxis
  • Quality-adjusted life years (QALY)

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Health economic models in hemophilia A and utility assumptions from a clinician's perspective'. Together they form a unique fingerprint.

Cite this